Core Viewpoint - Karyopharm Therapeutics Inc. reported mixed results from its Phase 3 SENTRY trial for myelofibrosis, leading to a decline in its stock price [1] Group 1: Trial Results - The SENTRY trial met its first co-primary endpoint, showing a significant improvement in spleen volume reduction of 35% or more for patients treated with selinexor plus ruxolitinib [2] - The trial indicated a promising overall survival signal, with a greater than 50% reduction in the risk of death compared to ruxolitinib alone [3] - 50% of patients on the combination achieved SVR35 at week 24, compared to 28% for those on ruxolitinib alone [4] Group 2: Symptom Scores and Secondary Endpoints - Patients on the combination treatment reported a 9.89-point improvement in symptoms, while those on ruxolitinib alone reported a 10.86-point improvement [5] - The trial did not meet its second co-primary endpoint of absolute total symptom score, and no meaningful differences were observed in secondary endpoints such as progression-free survival and hemoglobin stabilization [6] Group 3: Future Plans and Financials - Karyopharm plans to further evaluate trial endpoints and share additional data at an upcoming medical meeting, with a manuscript submission expected to a peer-reviewed journal [7] - The company announced a private placement of approximately $30 million, with potential additional gross proceeds of about $44 million if accompanying warrants are exercised [8] Group 4: Analyst Outlook - Analysts maintain a bullish outlook on Karyopharm, with the stock carrying a Buy Rating and an average price target of $42.17 [9] - Karyopharm shares were down 17.43% at $6.04 at the time of publication [9]

Karyopharm Therapeutics Conference Call Summary Company Overview - **Company**: Karyopharm Therapeutics (NasdaqGS: KPTI) - **Focus**: Development of treatments for myelofibrosis, particularly the combination of selinexor and ruxolitinib Key Industry Insights - **Industry**: Myelofibrosis treatment - **Current Landscape**: Myelofibrosis remains a disease with significant unmet needs, with current therapies providing modest spleen responses and limited disease modification. JAK inhibitors are the only approved class of therapies, highlighting the need for new treatment options that can improve patient outcomes, especially overall survival [1][2][94] Core Findings from the SENTRI Trial - **Trial Design**: Phase III SENTRI trial evaluated selinexor in combination with ruxolitinib in JAK inhibitor-naive myelofibrosis patients. A total of 353 patients were randomized in a 2-to-1 ratio [8][9] - **Primary Endpoints**: The trial had two co-primary endpoints: spleen volume reduction (SVR35) and absolute total symptom score (TSS) at week 24 [9] - **Efficacy Results**: - **SVR35 Rates**: The combination therapy achieved SVR35 rates of 50% compared to 28% for ruxolitinib alone, with a p-value of less than 0.0001, indicating a highly significant improvement [10] - **Overall Survival**: The combination demonstrated a greater than 50% reduction in the risk of death compared to ruxolitinib alone, with overall survival events at 4.7% for the combination versus 10.2% for ruxolitinib, corresponding to a hazard ratio of 0.43 and a nominal p-value of 0.0222 [11] - **Variant Allele Frequency (VAF)**: VAF reductions greater than or equal to 20% at week 24 were observed in 32% of combination-treated patients versus 24% of ruxolitinib-treated patients, suggesting potential disease modification [12] Safety Profile - **Adverse Events**: The safety profile was consistent with known profiles of selinexor and ruxolitinib, with no new safety signals identified. The most common treatment-emergent adverse events included thrombocytopenia (59%), anemia (57%), and nausea (57%) [14][15] - **Grade 3+ Adverse Events**: Observed in 14.5% of patients treated with the combination versus 8.6% for ruxolitinib alone, indicating a manageable safety profile [80] Implications for Treatment - **Clinical Significance**: The results suggest that the combination of selinexor and ruxolitinib could be a meaningful new treatment option for myelofibrosis, with rapid and sustained improvements in spleen volume and a promising overall survival signal [16][26] - **Future Directions**: Karyopharm plans to engage with the FDA regarding the SENTRI data and potential sNDA filing, as well as present findings at upcoming medical meetings [26] Additional Considerations - **Patient Population**: The combination therapy may be particularly beneficial for patients with severe splenomegaly and high symptom burden, although the exact patient profile for optimal use remains to be fully defined [75] - **NCCN Guidelines**: The potential for inclusion in NCCN guidelines could facilitate broader adoption of the combination therapy in clinical practice [50][49] Conclusion - The SENTRI trial results represent a significant advancement for Karyopharm and the myelofibrosis community, indicating the potential for improved treatment outcomes and addressing unmet needs in this patient population [94]

Core Insights - Karyopharm Therapeutics Inc. reported positive topline results from its Phase 3 SENTRY trial of selinexor in combination with ruxolitinib for frontline myelofibrosis, leading to a more than 15% increase in share price during pre-market trading [1] Group 1: Trial Results - The trial met its first co-primary endpoint, showing a statistically significant improvement in spleen volume reduction of at least 35% (SVR35) in patients treated with the combination compared to ruxolitinib alone [1] - At week 24, 50% of patients receiving the selinexor combination achieved SVR35, compared to 28% in the ruxolitinib-only group [2] - The combination treatment showed earlier and sustained responses, with 49% achieving SVR35 at week 12 versus 20% for ruxolitinib alone, and 47% at week 36 compared to 23% [2] Group 2: Symptom Improvement - Symptom improvement was comparable between the two groups, with a 9.89-point reduction in total symptom score for the combination group versus a 10.86-point reduction for the ruxolitinib-only group at week 24 [3] Group 3: Overall Survival and Future Plans - The combination demonstrated a promising overall survival signal with a hazard ratio of 0.43, and the company will continue to follow survival data to maturity [4] - Karyopharm plans to meet with the U.S. Food and Drug Administration to discuss the trial data and a potential supplemental new drug application filing [4]

Core Insights - Karyopharm's Phase 3 SENTRY trial demonstrated a statistically significant improvement in spleen volume reduction (SVR35) for patients treated with a combination of selinexor and ruxolitinib compared to ruxolitinib alone, meeting its first co-primary endpoint [1][10] - The trial did not meet its second co-primary endpoint of absolute total symptom score (Abs-TSS), with similar symptom improvements observed across both treatment arms [1][3] - A promising overall survival signal was noted, with a greater than 50% reduction in the risk of death for the combination therapy compared to ruxolitinib alone [1][3] - Evidence of potential disease modification was observed, with more patients achieving a 20% reduction in variant allele frequency (VAF) at week 24 in the combination arm [1][4] Spleen Volume Reduction - 50% of patients receiving the combination achieved SVR35 at week 24, compared to 28% for ruxolitinib alone (one-sided p<0.0001) [1][10] - Rapid spleen volume reduction was evident, with 49% of patients on the combination achieving SVR35 at week 12 versus 20% for ruxolitinib alone [1][10] - Sustained reduction was observed, with 47% of patients on the combination achieving SVR35 at week 36 compared to 23% for ruxolitinib alone [1][10] Symptom Improvement - Similar improvements in Abs-TSS were reported for both treatment arms at week 24, with a 9.89 point improvement for the combination and a 10.86 point improvement for ruxolitinib alone [1][10] Overall Survival - The combination therapy showed a promising overall survival signal with a hazard ratio of 0.43 (95% CI [0.19, 1.00], nominal one-sided p=0.0222) [1][3] - Post-hoc analyses suggested that achieving SVR35 may predict overall survival [1][10] Variant Allele Frequency Reduction - At week 24, 32% of patients in the combination arm achieved a 20% reduction in VAF compared to 24% in the ruxolitinib arm [1][10] Safety and Tolerability - The combination therapy exhibited a manageable safety profile consistent with the known profiles of selinexor and ruxolitinib, with no new safety signals identified [1][5] - The most common treatment-emergent adverse events included thrombocytopenia (59% in the combination arm), anemia (57%), and nausea (57%) [6][10] Next Steps - Karyopharm plans to meet with the FDA to discuss the trial data and potential supplemental new drug application (sNDA) filing [1][7] - Additional data from the SENTRY trial will be shared at an upcoming medical meeting, and a manuscript is expected to be submitted to a peer-reviewed journal [7][10]

Core Insights - Mesoblast Limited announced that remestemcel-L demonstrated superior efficacy and safety compared to ruxolitinib for treating steroid-refractory acute graft versus host disease (SR-aGvHD) at the 67th ASH Annual meeting [1][2] Company Overview - Mesoblast is a global leader in developing allogeneic cellular medicines for severe inflammatory diseases, utilizing a proprietary mesenchymal lineage cell therapy technology platform [4] - The company has a strong intellectual property portfolio with over 1,000 granted patents or applications, providing commercial protection until at least 2044 in major markets [7] - Mesoblast's manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf cellular medicines, ensuring availability to patients worldwide [8] Product Information - Ryoncil (remestemcel-L) is the first FDA-approved mesenchymal stromal cell therapy for pediatric patients aged 2 months and older with SR-aGvHD [5] - The therapy is being developed for additional indications, including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease, as well as heart failure and chronic low back pain [6] Clinical Study Findings - The meta-analysis included 2,732 patients across 11 studies, with remestemcel-L showing superior outcomes in complete and overall remission compared to ruxolitinib [2] - Both therapies improved quality of life, but remestemcel-L had better results in terms of hematology, cardiac, and hepatic adverse events [2]

Karyopharm Therapeutics FY Conference Summary Company Overview - **Company**: Karyopharm Therapeutics (NasdaqGS: KPTI) - **Key Product**: XPOVIO (selinexor), a first-in-class oral Exportin-1 inhibitor primarily for relapse refractory multiple myeloma and diffuse large B-cell lymphoma, with ongoing development for myelofibrosis and endometrial cancer [1][2] Core Points and Arguments Product and Mechanism - **Selinexor Mechanism**: Acts as an XPO1 inhibitor, blocking the Exportin-1 protein, which retains tumor suppressors like p53 within the nucleus, thereby inhibiting cancer cell proliferation [3][4] - **Myelofibrosis Context**: Current treatments mainly target the JAK-STAT pathway, but selinexor also addresses p53 and NF-B pathways, which are crucial in myelofibrosis [4] Financial Performance - **Q3 Revenue**: Reported revenues of approximately $32 million, with guidance for $110-$120 million for the year, indicating slight growth compared to the previous year [5][6] Market Utilization - **Multiple Myeloma**: Selinexor is primarily used in the community setting (60% of utilization) and academic settings (40%), positioned as a treatment option for patients post anti-CD38 therapy [6][7] - **Growth Strategy**: Focus on expanding usage in multiple myeloma while emphasizing the upcoming myelofibrosis opportunity [9][11] Myelofibrosis Opportunity - **Current Standard of Care**: Ruxolitinib has been the standard treatment for over a decade, but only 30% of patients achieve significant spleen volume reduction (SVR35) [15][17] - **Combination Therapy**: Selinexor combined with ruxolitinib aims to improve SVR35 rates and address symptoms and anemia more effectively than ruxolitinib alone [18][22] - **Clinical Trial Data**: The ESSENTIAL trial showed a nearly 30% SVR35 rate in heavily pretreated patients, while a phase 1 study indicated a 79% SVR35 rate in newly diagnosed patients [21][22] Upcoming Trials and Data - **Phase 3 SENTRY Trial**: Designed to evaluate the combination of selinexor and ruxolitinib in frontline myelofibrosis patients, with primary endpoints of SVR35 and total symptom score (TSS) [28][29] - **Expected Data Release**: Top-line data from the SENTRY trial is anticipated in March 2026 [11][54] Market Potential - **Revenue Opportunity**: Estimated peak revenue opportunity for myelofibrosis in the U.S. is approximately $1 billion, with a significant overlap in prescriber base from multiple myeloma [42][43] - **Patient Population**: Approximately 20,000 prevalent patients in the U.S. with 6,000 new intermediate to high-risk diagnoses annually [43][44] Endometrial Cancer Development - **Phase 3 XPORT-EC-042 Trial**: Focused on p53 wild type patients, leveraging previous positive data showing a median progression-free survival (PFS) of 40 months compared to 5 months for placebo [49][51] - **Data Expectations**: Results from this trial are expected in mid-2026 [51] Financial Position - **Debt and Cash Runway**: Karyopharm has $231 million in debt with deferred interest payments until Q2 2026, providing a cash runway to reach pivotal data readouts [54] Additional Important Points - **Safety Profile**: Combination therapy shows potential for improved gastrointestinal and hematologic safety compared to ruxolitinib alone [31][32] - **Commercialization Strategy**: Existing capabilities and market research indicate a strong intent to prescribe the combination therapy among physicians [44][45] This summary encapsulates the key insights from Karyopharm Therapeutics' FY conference, highlighting the company's strategic focus on myelofibrosis and endometrial cancer, alongside its financial positioning and market opportunities.

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $44 million, an increase of 13.4% compared to $38.8 million in Q3 2024 [26] - U.S. net product revenue for XPOVIO grew 8.5% year over year to $32 million [26] - License and other revenue was $12 million in Q3 2025, up nearly 30% from Q3 2024 [27] - Gross to net provisions for XPOVIO were 27% in Q3 2025, consistent with Q2 2025 and down from 31% in Q3 2024 [26] - The net loss was $33.1 million, or $3.82 per share on a GAAP basis, with more than half of this loss driven by non-operational items [29] Business Line Data and Key Metrics Changes - XPOVIO net product revenue in Q3 2025 was $32 million, reflecting continued strength in the multi-biomodal market [20] - The company is focused on advancing late-stage clinical programs, particularly SENTRY and ECO42, which are expected to be transformative [6] Market Data and Key Metrics Changes - The company sees a significant opportunity in the myofibrosis market, with approximately 20,000 patients living with the condition in the U.S. [23] - There are about 4,000 newly diagnosed patients each year in the U.S. with intermediate to high-risk myofibrosis who could benefit from the combination therapy [23] Company Strategy and Development Direction - The company aims to redefine the standard of care for myofibrosis through the combination of selinexor and ruxolitinib [4] - The strategy includes maintaining financial discipline while driving growth across the XPOVIO franchise and advancing clinical programs [6] - The company is preparing for a potentially transformative commercial launch in myofibrosis, driven by high unmet needs and lack of innovation in the market [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming top-line data from the SENTRY trial, expected in March 2026, which could reshape treatment paradigms [4] - The company has secured approximately $100 million in financial flexibility, extending its cash runway into Q2 2026 [5] - Management emphasized the importance of executing with clarity and purpose to deliver innovative cancer therapies [7] Other Important Information - The company has completed enrollment in the phase three SENTRY trial, marking a pivotal moment for its myofibrosis program [4] - The company has a strong commercial foundation and existing capabilities that will support a rapid launch if the trial data is positive [25] Q&A Session Summary Question: Can you walk through what we should see for MF data in March 2026? - Management anticipates providing top-line details, including primary endpoints of SVR35 and absolute TSS, with potential secondary endpoints [34][35] Question: What is the size of the sales force for myofibrosis? - Minimal additions to the commercial structure are expected due to strong overlap with existing capabilities [36] Question: Are there any milestones associated with recent financial restructuring? - No specific triggers related to positive data were mentioned, but positive data could significantly enhance value [37] Question: Can you discuss the commercial potential launch in myofibrosis? - The company is leveraging learnings from multiple myeloma to optimize trial design and patient outcomes [48][49]

Core Insights - Incyte Corporation (NASDAQ:INCY) is identified as one of the most undervalued stocks on NASDAQ, particularly following the recent updates on its clinical trials for povorcitinib [1][2] - Citizens JMP has maintained a Market Perform rating for Incyte, highlighting the ongoing Phase 3 trials for povorcitinib in various conditions, including hidradenitis suppurativa [1][2] - The potential peak revenue for povorcitinib is estimated at $1 billion, but Incyte's shares are considered fairly valued as the company navigates a projected $3 billion+ patent gap for ruxolitinib by 2029 [2] Company Overview - Incyte Corporation is a leading American pharmaceutical company focused on developing treatments for various diseases, including cancer [3]

Core Insights - Karyopharm Therapeutics has completed enrollment in the Phase 3 SENTRY trial, which is evaluating the combination of selinexor and ruxolitinib in patients with myelofibrosis [1][2] - The trial aims to provide top-line data in March 2026, with the potential for selinexor plus ruxolitinib to become the first approved combination therapy for myelofibrosis [2] - Myelofibrosis is a rare blood cancer affecting approximately 20,000 patients in the U.S. and 17,000 in the EU, with current treatment options limited to JAK inhibitors [3] Company Overview - Karyopharm Therapeutics is a commercial-stage pharmaceutical company focused on developing novel cancer therapies, particularly through its lead compound, XPOVIO (selinexor), which is an oral exportin 1 (XPO1) inhibitor [5][12] - XPOVIO is approved in the U.S. for multiple oncology indications and has received regulatory approvals in various countries, including the EU and China [6][12] - The company is advancing its pipeline to address high unmet needs in cancers such as multiple myeloma, endometrial cancer, and diffuse large B-cell lymphoma [12] Clinical Trial Details - The SENTRY trial enrolled 353 patients and evaluates a once-weekly dose of 60 mg of selinexor in combination with ruxolitinib compared to placebo plus ruxolitinib [2] - Co-primary endpoints include spleen volume response rate of 35% at week 24 and average change in absolute total symptom score over 24 weeks [2] - The trial targets JAKi-naïve myelofibrosis patients with platelet counts greater than 100 x 10/L, with a randomization ratio of 2-to-1 favoring the selinexor arm [2] Industry Context - Myelofibrosis is characterized by bone marrow fibrosis, leading to anemia and other debilitating symptoms, with current treatments often resulting in transfusion dependence [3] - The myelofibrosis community is in need of new therapies, as existing JAK inhibitors have limitations, including a high discontinuation rate due to anemia [3] - The development of new combination therapies like selinexor plus ruxolitinib could significantly impact treatment paradigms for myelofibrosis patients [2][3]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $37.9 million, down from $42.8 million in 2024, primarily due to $6 million of non-recurring license-related revenue recognized in 2024 [38] - U.S. XPOVIO net product revenue for 2025 was $29.7 million, compared to $28 million in 2024, reflecting a 6% increase [32][39] - The gross to net provisions for XPOVIO in Q2 2025 were 26.8%, down from 45% in Q1 2025 and 29.3% in 2024 [39] - The company reported a net loss of $37.3 million or $4.32 per share on a GAAP basis, which includes $11.2 million in interest expense [42] Business Line Data and Key Metrics Changes - XPOVIO net product revenue was consistent, with the community setting driving approximately 60% of total U.S. sales [32] - The company expects net product revenue for the full year 2025 to be in the range of $110 million to $120 million [39] Market Data and Key Metrics Changes - The peak revenue potential for selinexor in myelofibrosis is estimated to be up to $1 billion annually in the U.S. alone [10][35] - Royalty revenue increased by 28% to $1.6 million in 2025 compared to 2024, reflecting increased global demand for XPOVIO and NexpoVIO [34] Company Strategy and Development Direction - The company is focused on enhancing liquidity and maximizing value while preparing for potential launches in myelofibrosis and endometrial cancer [6][45] - The company aims to redefine the standard of care for myelofibrosis with the combination of selinexor and ruxolitinib, pending positive data from ongoing trials [9][45] Management's Comments on Operating Environment and Future Outlook - Management acknowledged financial constraints with a near-term debt maturity in October and is actively engaged with lenders to enhance liquidity [6] - The company remains optimistic about the potential for selinexor plus ruxolitinib to improve treatment outcomes for myelofibrosis patients [9][45] Other Important Information - The company announced a 20% reduction in workforce to optimize costs, expecting to lower annual spend by approximately $13 million in 2026 [43] - The company exited 2025 with cash and equivalents of $52 million, down from $109.1 million at the end of 2024 [43] Q&A Session Summary Question: Concerns about myelofibrosis readout and preparation for multiple data readouts - Management expressed excitement about the upcoming readouts and confidence in leveraging existing commercial capabilities to prepare for potential launches in myelofibrosis and endometrial cancer [50][51] Question: Impact of higher baseline TSS on trial results - Management indicated that higher baseline TSS could lead to more meaningful outcomes in the trial, with ongoing monitoring of patient characteristics [60][61] Question: Reasons for lower rates of grade three anemia with combination therapy - Management attributed lower rates of grade three anemia to potential disease modification effects of selinexor, including reductions in key cytokines [62][63] Question: Confidence in blinded safety data holding once unblinded - Management expressed optimism about the safety profile observed in blinded data, noting consistency with historical ruxolitinib safety data [71][72]